Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rdGCM-1012
- Development stage
- Preclinical
- Lead developer
- Gencellmed
- Modality
- Gene Therapies
01
Overview
rdGCM-1012 is a preclinical-stage gene therapy candidate developed by Gencellmed for aesthetic applications, primarily focused on wrinkle care. The therapy utilizes a replication-defective Herpes Simplex Virus type 1 (HSV-1) viral vector platform. This vector is engineered to be non-replicating to ensure safety while leveraging the virus's natural ability to efficiently transduce skin cells. Although the specific therapeutic payload has not been disclosed, the program aims to provide long-lasting aesthetic improvements by delivering genes that promote skin rejuvenation or structural integrity.
- Other names
- rdGCM-1012rdGCM1012rdGCM 1012
Beyond the preview
Go deeper on rdGCM-1012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rdGCM-1012.